Advance Journal of Pharmaceutical Research & Review
Volume 2, Issue 1, January 2025, PP: 31-39, ISSN No: 3048-491X

Current Perspectives on the Diagnosis of Avascular Necrosis: Challenges and Innovations

Aasawari S. Kapse [1], Raksha P. Khandre[2], Snehal M. Jamgade[3], Rupali U. Chavan[4], Dr. M.D. Kitukale [5]

[1,2,3]Bachelor's Student, Department of Pharmacology, P Wadhwani College of Pharmacy, Girija Nagar Yavatmal, 445001.

[4] Associate Professor, Department of Pharmacology, P Wadhwani College of Pharmacy, Girija Nagar Yavatmal, 445001.

[5]Principal, Department of Pharmaceutical Chemistry, P Wadhwani College of Pharmacy, Girija Nagar Yavatmal, 445001.

Corresponding author[4]

Date of Submission: 07-01-2025 Date of acceptance: 18-01-2025

Abstract

Avascular necrosis (AVN) is a debilitating condition characterized by bone ischemia and structural collapse, leading to significant morbidity. Early diagnosis is critical for effective management, yet challenges persist due to its insidious onset, non-specific symptoms, and limitations of traditional diagnostic modalities. This systematic review examines the pathophysiology, clinical presentation, and diagnostic advancements in AVN, emphasizing their implications for treatment strategies. Conventional imaging techniques, while widely used, face limitations in detecting early-stage disease. Emerging modalities such as Single Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and artificial intelligence (AI)-driven imaging offer enhanced diagnostic precision. Biomarkers and genetic studies represent promising non-invasive tools for early detection. Management strategies are closely tied to diagnostic accuracy, with early-stage interventions focusing on pharmacotherapy and core decompression, while advanced stages necessitate surgical approaches. Innovations in diagnostic tools and multidisciplinary care are paving the way for personalized management and improved outcomes. However, challenges such as diagnostic delays, variability in criteria, and access disparities remain significant. This review underscores the need for standardized protocols, cost-effective technologies, and further research to optimize AVN diagnosis and treatment.

Keywords*: Avascular necrosis, early diagnosis, imaging advancements, biomarkers, artificial intelligence, personalized medicine, SPECT, PET.*

I. Introduction

Avascular necrosis (AVN), also referred to as osteonecrosis, is a progressive disease characterized by the death of bone tissue due to compromised blood supply [1]. It most commonly affects the femoral head, though other skeletal sites may also be involved. AVN progresses through distinct stages, ultimately leading to structural collapse and debilitating joint pain if left untreated [2]. Early diagnosis of AVN is critical to halting disease progression and optimizing patient outcomes, as interventions in the early stages can prevent significant morbidity and obviate the need for invasive surgical procedures [3].

The importance of timely diagnosis stems from the insidious onset of AVN, which often presents with non-specific symptoms. Delays in recognition can result in significant cartilage damage and reduced quality of life. As the disease advances, it imposes an increasing burden on healthcare systems due to the cost of joint replacement surgeries and associated rehabilitation [4]. Hence, understanding the diagnostic landscape of AVN is pivotal in guiding clinical practice and enhancing the efficacy of management strategies.

The objectives of this systematic review are threefold. First, to provide an overview of the underlying pathophysiology and clinical presentation of AVN to contextualize diagnostic challenges. Second, to evaluate the efficacy and limitations of current diagnostic modalities, with a particular focus on imaging techniques and emerging technologies. Finally, to identify gaps in existing diagnostic frameworks and explore innovations poised to transform the field, including artificial intelligence and advanced imaging technologies [5,6].

This review underscores the need for an integrated diagnostic approach to AVN, which accounts for clinical, radiological, and biochemical parameters. By synthesizing existing evidence, the study aims to inform clinicians and researchers about the most effective diagnostic practices, thereby enhancing early detection and improving patient outcomes [7].

II. Pathophysiology of Avascular Necrosis

Avascular necrosis (AVN) arises from the disruption of blood supply to the bone, leading to cellular death, structural compromise, and eventual joint collapse [8]. The pathophysiology is multifactorial and complex, involving vascular occlusion, increased intraosseous pressure, and reduced perfusion. Trauma, such as fractures or dislocations, is a common etiology, directly damaging the vasculature supplying the bone. Non-traumatic causes include corticosteroid use, excessive alcohol consumption, and conditions like sickle cell anaemia and systemic lupus erythematosus [9,10].

The disease process begins with ischemia-induced osteocyte death, which triggers an inflammatory cascade. This response results in bone marrow oedema and further compromises microvascular integrity. Subsequent resorption of necrotic bone by osteoclasts creates mechanical instability, leading to subchondral fracture and joint deformation [11].

Risk factors for AVN are diverse, encompassing both modifiable and non-modifiable elements. While younger populations are at risk due to trauma, middle-aged individuals often develop AVN due to metabolic or systemic conditions. Gender-based differences suggest males are more frequently affected, particularly in cases involving alcohol and corticosteroids [12].

Staging AVN is essential for diagnosis and treatment planning. The Ficat-Arlet classification system, widely used for staging, categorizes the disease into four stages based on radiological and clinical findings. In Stage I, MRI detects early ischemic changes, while Stage II reveals sclerosis and cyst formation. Stage III is marked by subchondral collapse, and Stage IV involves secondary osteoarthritis [13].

Table 1: Summary of Ficat-Arlet Staging System

Stage	Radiological Findings	Clinical Presentation
Stage I	Regular X-rays; MRI shows ischemia	Mild pain, no functional limitation
Stage II	Sclerosis, cysts on X-ray	Pain increases, mild restriction
Stage III	Subchondral collapse	Significant pain, limited mobility
Stage IV	Joint space narrowing, osteoarthritis	Severe pain, functional impairment

The interplay of mechanical and biological factors in AVN progression underscores the importance of early detection. This understanding is critical to prevent the irreversible damage that characterizes later stages [14].



Figure 1: Flowchart: Pathophysiology of AVN

III. Clinical Presentation

Avascular necrosis (AVN) commonly presents with insidious, progressive symptoms, often delaying diagnosis and treatment [15]. The hallmark symptom is joint pain, typically localized to the groin, thigh, or buttock in cases involving the femoral head. Initially, the pain is intermittent and exacerbated by weight-bearing activities. As the disease progresses, patients experience constant pain, even at rest [16].

Clinical examination may reveal tenderness over the affected joint, a reduced range of motion, and pain with specific movements, such as internal or external hip rotation. Patients often report difficulty with activities of daily living, such as walking or climbing stairs, significantly impacting their quality of life [17].

Differential diagnosis is challenging due to symptom overlap with other conditions, including hip osteoarthritis, bursitis, and lumbar radiculopathy. In younger individuals, transient synovitis or stress fractures may mimic AVN [18]. Accurate differentiation is essential, as treatment strategies differ significantly among these conditions.

Table 2: Differential Diagnosis of AVN

Condition	Key Features	Diagnostic Tools
Hip Osteoarthritis	Morning stiffness, crepitus	X-ray (joint space narrowing)
Bursitis	Localized tenderness, swelling	Ultrasound
Lumbar Radiculopathy	Radiating pain, neurological deficits	MRI (spine imaging)

Transient Synovitis	Acute onset resolves within weeks	Exclusion by clinical course
Stress Fracture	Localized pain, history of repetitive trauma	MRI

The functional impact of AVN extends beyond physical pain, often leading to psychological distress due to loss of mobility and independence. Studies highlight a significant reduction in health-related quality of life (HRQoL) scores among affected individuals, emphasizing the need for timely intervention [19].



Figure 2: Flowchart: Clinical Presentation of AVN

IV. Current Diagnostic Modalities

4.1 Imaging Techniques

Imaging plays a pivotal role in diagnosing and staging avascular necrosis (AVN). X-rays are often the initial investigation due to their accessibility and cost-effectiveness. However, they are limited in detecting early-stage AVN, as radiographic changes such as sclerosis or subchondral collapse are visible only in advanced stages [20].

MRI is considered the gold standard for diagnosing AVN, especially in its early stages. It has a sensitivity of over 90% and can detect bone marrow oedema, ischemic changes, and early necrosis, which are not evident on X-rays [21]. Coronal and sagittal views provide detailed anatomical visualization, aiding in precise staging. MRI is beneficial in assessing bilateral involvement, which is common in AVN cases [22].

Bone scintigraphy, while less sensitive than MRI, is effective in identifying multifocal AVN. It involves using radioactive tracers like technetium-99m to visualize areas of altered bone metabolism. This modality is useful in cases with high suspicion of AVN but inconclusive MRI findings [23].

Though not routinely used for early diagnosis, CT scans provide excellent detail of bony architecture and are valuable for assessing subchondral fractures and joint congruity in advanced stages. A CT-guided biopsy can also confirm AVN in atypical presentations [24].

Table 3: Comparison of Imaging Modalities in AVN Diagnosis

Modality	**Sensitivity (%)**	**Specificity (%)**	**Strengths**	**Limitations**
X-ray	50-70	80-90	Widely available, cost-effective	Insensitive in early stages
MRI	>90	>90	High sensitivity, early detection	Expensive, limited availability
Bone Scintigraphy	80-85	60-70	Detects multifocal AVN	Low specificity, radiation exposure
CT-Scan	85-90	75-80	Detailed bony architecture	Poor early-stage sensitivity



Figure 3: Representation of Comparison of Imaging Modalities in AVN Diagnosis

4.2 Emerging Technologies

Emerging technologies offer promising advancements in AVN diagnosis. Single-photon emission computed tomography (SPECT) and positron emission tomography (PET) provide enhanced functional imaging compared to traditional scintigraphy, improving the detection of early ischemic changes [25]. Hybrid modalities like PET-CT further integrate anatomical and metabolic imaging, allowing comprehensive assessment [26].

Biomarkers represent another frontier in AVN diagnostics. Elevated levels of specific markers, such as vascular endothelial growth factor (VEGF) and bone turnover markers, are associated with ischemic processes and bone remodelling in AVN. Although currently in experimental stages, these biomarkers hold the potential for non-invasive, early detection [27].

Initial Assessment Patient history and physical examination
First-line Imaging X-rays (rule out advanced disease)
Gold Standard Imaging MRI (detect early-stage changes)
Supplementary Techniques Bone Scintigraphy (multifocal involvement) CT-Scan (structural details, subchondral fracture)
Emerging Diagnostics SPECT/PET (functional imaging) Biomarker analysis (non-invasive detection)

Figure 4: Diagnostic Pathway for AVN

V. Challenges in Diagnosis

Diagnosing avascular necrosis (AVN) is fraught with challenges, primarily due to its insidious onset and diverse etiologies. These obstacles often result in delayed diagnosis, misdiagnosis, or underdiagnosis, exacerbating disease progression and compromising treatment outcomes [28].

5.1 Delays in Recognition and Referral

AVN frequently presents with non-specific symptoms, such as vague joint pain, leading to misattribution to conditions like arthritis or muscle strain. Primary care physicians may not immediately suspect AVN, particularly in younger patients or those without known risk factors, resulting in delayed specialist referral [29].

5.2 Variability in Diagnostic Criteria

The lack of standardized diagnostic protocols contributes to inconsistencies in AVN detection. Imaging modalities are often used at the discretion of clinicians, leading to variability in sensitivity and specificity across settings. While MRI is considered the gold standard, access limitations in resource-poor regions create diagnostic disparities [30].

5.3 Limitations of Current Imaging Techniques

Each imaging modality has its limitations. X-rays, though widely available, are insensitive to early-stage AVN. Bone scintigraphy lacks specificity, often yielding false positives in conditions with increased bone turnover. CT scans provide structural detail but fail to detect early ischemic changes [31]. Even MRI, despite its high sensitivity, may miss subtle lesions or fail to distinguish AVN from other conditions like transient bone marrow oedema syndrome [32].

Table 4: Diagnostic Challenges in AVN

Challenges	Impact on Diagnosis	Potential Solutions
Non-specific symptoms	Delayed recognition	Increased clinician awareness
Lack of standardized criteria	Variability in detection	Development of uniform diagnostic guidelines
Imaging limitations	Misdiagnosis delayed treatment	Integration of advanced imaging modalities
Accessibility issues	Disparities in diagnosis	Improving healthcare infrastructure

5.4 Socioeconomic and Geographical Barriers

Access to advanced diagnostic tools like MRI is often limited in rural or low-resource settings. High costs further restrict their use, especially in countries with inadequate healthcare coverage. This disparity leads to delayed diagnosis and poorer outcomes in underserved populations [33].



Figure 5: Flowchart: Challenges in AVN Diagnosis

5.5 Overcoming Challenges

Efforts to mitigate these challenges include increasing clinician awareness of AVN risk factors and symptoms, particularly in high-risk populations such as individuals on long-term corticosteroid therapy or those with a history of trauma [34]. Furthermore, adopting uniform diagnostic protocols and leveraging emerging technologies like biomarkers and artificial intelligence can enhance diagnostic precision and accessibility [35].

VI. Innovations in Diagnosis

Advancements in diagnostic technology are revolutionizing the early detection and management of avascular necrosis (AVN). These innovations address existing challenges, such as delayed recognition, variability in diagnostic criteria, and the limitations of traditional imaging modalities, paving the way for more precise and accessible diagnosis [36].

6.1 Advances in Imaging Technology

Emerging imaging modalities, such as Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET), offer improved functional imaging capabilities. SPECT, particularly when combined with CT, enables detailed assessment of bone metabolism and structure, making it invaluable in early AVN diagnosis [37]. PET, often used in conjunction with advanced tracers, provides insights into bone remodelling and ischemic changes, offering superior sensitivity in identifying subclinical lesions [38].

Three-dimensional (3D) imaging reconstructions from MRI and CT scans have also shown promise in enhancing diagnostic accuracy by providing a more detailed representation of the affected bone, aiding in precise staging [39].

6.2 Role of Artificial Intelligence and Machine Learning

Artificial intelligence (AI) and machine learning (ML) algorithms are increasingly being integrated into AVN diagnosis. These technologies analyze imaging data to detect subtle abnormalities, identify early ischemic changes, and predict disease progression. Studies have demonstrated that AI-driven diagnostic systems can achieve comparable, if not superior, accuracy to expert radiologists while reducing interobserver variability [40].

Table 5: Innovations in Imaging for AVN

Technology	Key Features	Diagnostic Advantages
SPECT/CT	Combines functional and structural imaging	Early lesion detection, detailed assessment
PET	Advanced tracers for bone remodelling	High sensitivity for ischemic changes
3D Imaging	Comprehensive visualization	Enhanced staging accuracy
AI/ML in Imaging	Automated data analysis	Reduced variability, improved early diagnosis

6.3 Biomarkers and Genetic Studies

The use of biomarkers offers a promising non-invasive diagnostic approach. Biomarkers such as vascular endothelial growth factor (VEGF), matrix metalloproteinases (MMPs), and bone-specific alkaline phosphatase (BSAP) are associated with bone ischemia and remodelling, providing insights into disease activity [41]. Advances in genetic studies have also identified polymorphisms associated with AVN susceptibility, potentially enabling personalized diagnostic and therapeutic strategies [42].



Figure 6: Flowchart: Emerging Innovations in AVN Diagnosis

6.4 Future Directions for Research

Despite these advancements, further research is essential to validate the clinical utility of emerging technologies. Large-scale studies are required to standardize biomarker use and evaluate AI systems across diverse populations. Developing cost-effective and portable imaging solutions can also improve access to advanced diagnostics in resource-limited settings [43].

The following section will explore how accurate diagnosis influences treatment strategies and improves outcomes in AVN management.

VII. Management Implications Based on Diagnosis

Accurate diagnosis of avascular necrosis (AVN) is crucial in determining appropriate treatment strategies, which vary significantly based on disease stage and severity. Early and precise diagnosis directly impacts clinical decision-making, enabling interventions that can preserve joint function and delay or prevent disease progression [44].

7.1 Importance of Accurate Staging

The Ficat-Arlet classification and other staging systems rely on imaging findings to guide treatment decisions. In the early stages (I and II), non-surgical management options such as pharmacotherapy, lifestyle modifications, and physiotherapy are often effective. Bisphosphonates, for example, are used to inhibit osteoclastic activity and reduce bone resorption, while anticoagulants may improve microcirculation [45].

In advanced stages (III and IV), where structural collapse has occurred, surgical interventions become necessary. Core decompression, vascularized bone grafting, and total joint replacement are tailored to the extent of joint damage. Accurate staging using advanced imaging modalities such as MRI ensures that treatment is appropriately aligned with disease progression [46].

7.2 Surgical vs. Non-Surgical Management

Timely diagnosis enables early-stage interventions that may obviate the need for surgery. For instance, core decompression performed before structural collapse has shown high success rates in halting disease progression. Conversely, delayed diagnosis often limits treatment options to more invasive procedures like joint arthroplasty [47].

Table 6: Management Strategies Based on AVN Stage

Stages	Common Findings	Management Options
Stage I	Edema, no structural change	Pharmacotherapy, lifestyle modifications
Stage II	Early necrosis	Core decompression, bisphosphonates
Stage III	Subchondral collapse	Bone grafting, stem cell therapy
Stage IV	Joint destruction	Total joint replacement

7.3 Role of Diagnosis in Multidisciplinary Care

AVN management often involves a multidisciplinary team, including radiologists, orthopaedic surgeons, and physiotherapists. Accurate imaging and biomarker findings allow for tailored treatment plans that address both physical and functional aspects of care. For instance, physiotherapy can be initiated early in the disease to improve mobility and reduce pain, while surgeons can plan for precise interventions [48].



Figure 6: Flowchart: Management Pathway for AVN Based on Diagnosis

7.4 Implications for Future Management

Emerging diagnostic tools such as AI-driven imaging and biomarkers hold promise for more personalized treatment approaches. These innovations may help stratify patients based on risk profiles, enabling proactive interventions that improve long-term outcomes and reduce healthcare costs [49].

VIII. Conclusion

Avascular necrosis (AVN) remains a significant clinical challenge due to its complex pathophysiology, variable presentation, and diagnostic limitations. This systematic review highlights the critical role of early and accurate diagnosis in improving patient outcomes, emphasizing the limitations of traditional modalities and the potential of emerging technologies.

Conventional imaging techniques such as X-rays, MRI, CT scans, and bone scintigraphy, though practical, face challenges in early-stage diagnosis and accessibility in resource-limited settings. Advances in imaging technologies, including SPECT and PET, along with the integration of artificial intelligence (AI) and machine learning (ML), have shown promise in enhancing diagnostic accuracy and reducing variability. Furthermore, biomarkers and genetic studies represent a frontier in non-invasive diagnostics, offering insights into disease mechanisms and progression.

Management strategies heavily depend on the stage of AVN, highlighting the importance of precise diagnosis. Early-stage interventions such as pharmacotherapy and core decompression can delay disease progression, while advanced stages often require surgical options like bone grafting or total joint replacement. Accurate staging facilitates personalized treatment, improving outcomes and preserving joint function.

Future research should focus on validating innovative diagnostic approaches, standardizing protocols, and addressing socioeconomic barriers to ensure equitable access to advanced diagnostic tools. Multidisciplinary care and the adoption of personalized medicine hold the key to optimizing AVN management. Continued advancements in technology and clinical practice are essential to mitigate the burden of this debilitating condition.

Acknowledgment

The authors would like to express their gratitude to the institutions, organizations, and individuals who contributed to this research. We acknowledge the support of our affiliated institutions for providing resources and logistical assistance. Additionally, we appreciate the constructive feedback from peer reviewers, which significantly improved the quality of this manuscript.

Conflict of Interest

The authors confirm that there are no competing interests with any institutions, organizations, or products that may influence the findings or conclusions of this manuscript.

References

[1]. Jones LC, Hungerford DS. Osteonecrosis: etiology, diagnosis, and treatment. Curr Opin Rheumatol. 2004;16(4):443-9.

[2]. Assouline-Dayan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum. 2002;32(2):94-124.

[3]. Mont MA, Jones LC, Hungerford DS. Nontraumatic osteonecrosis of the femoral head: ten years later. J Bone Joint Surg Am. 2006;88(5):1117-32.

[4]. Mankin HJ. Nontraumatic necrosis of bone (osteonecrosis). N Engl J Med. 1992;326(22):1473-9.

[5]. Ficat RP. Idiopathic bone necrosis of the femoral head. Early diagnosis and treatment. J Bone Joint Surg Br. 1985;67(1):3-9.

[6]. Hungerford DS. Bone marrow pressure, venography, and core decompression in ischemic necrosis of the femoral head. Instr Course Lect. 1984;33:302-8.

[7]. Steinberg ME, Hayken GD, Steinberg DR. A quantitative system for staging avascular necrosis. J Bone Joint Surg Br. 1995;77(1):34-41.

[8]. Hernigou P, Beaujean F. Treatment of osteonecrosis with autologous bone marrow grafting. Clin Orthop Relat Res. 2002;(405):14-23.

[9]. Koo KH, Kim R, Kim YS, Ahn IO, Cho SH, Song HR, et al. The risk period for developing osteonecrosis of the femoral head in patients on steroid treatment. Clin Rheumatol. 2002;21(4):299-303.

[10]. Powell C, Chang C, Naguwa SM, Cheema G, Gershwin ME. Steroid-induced osteonecrosis: an analysis of steroid dosing risk. Autoimmun Rev. 2010;9(11):721-43.

[11]. Hofmann S, Engel A, Neuhold A, Leder K, Kramer J, Plenk H Jr. Bone-marrow oedema syndrome and transient osteoporosis of the hip. J Bone Joint Surg Br. 1993;75(2):210-6.

[12]. Mitchell DG, Rao VM, Dalinka MK, Spritzer CE, Alavi A, Steinberg ME, et al. Femoral head avascular necrosis: correlation of MR imaging, radiographic staging, radionuclide imaging, and clinical findings. Radiology. 1987;162(3):709-15.

[13]. Chan KL, Mok CC. Glucocorticoid-induced avascular bone necrosis: diagnosis and management. Open Orthop J. 2012;6:449-57.□□

[14]. Hofmann S, Schneider W, Breitenseher M, Urban M, Plenk H Jr. "Transient osteoporosis" and "bone marrow oedema syndrome". Orthopade. 2001;30(7):535-42.□□

[15]. Hernigou P, Habibi L, Bachir D, Galacteros F. The natural history of symptomatic osteonecrosis in adults with sickle-cell disease. J Bone Joint Surg Am. 2006;88(12):2565-72.

[16]. Mont MA, Zywiel MG, Marker DR, McGrath MS, Delanois RE. The natural history of untreated asymptomatic osteonecrosis of the femoral head: a systematic literature review. J Bone Joint Surg Am. 2010;92(12):2165-70.

[17]. Hernigou P, Beaujean F. Treatment of osteonecrosis with autologous bone marrow grafting. Clin Orthop Relat Res. 2002;(405):14-23.

[18]. Mont MA, Marulanda GA, Jones LC, Saleh KJ, Gordon N, Hungerford DS. Avascular necrosis of the femoral head: evaluation and treatment. J Am Acad Orthop Surg. 2006;14(12):695-706.□□

[19]. Scully SP, Aaron RK, Urbaniak JR. Survival analysis of hips treated with core decompression or vascularized fibular grafting because of avascular necrosis. J Bone Joint Surg Am. 1998;80(9):1270-5.

[20]. Steinberg ME, Steinberg DR. Classification systems for osteonecrosis: an overview. Orthop Clin North Am. 2004;35(3):273-83

[21]. Hungerford DS. Treatment of osteonecrosis: avoidable or inevitable collapse. Orthop Clin North Am. 1993;24(4):639-43.

[22]. Mont MA, Einhorn TA, Sponseller PD, Hungerford DS. The trapdoor procedure: early clinical results in osteonecrosis of the femoral head. J Bone Joint Surg Br. 1998;80(1):56-62.

[23]. Koo KH, Kim R, Ko GH, Song HR, Jeong ST, Cho SH. Preventing collapse in early osteonecrosis of the femoral head. A randomized clinical trial of core decompression. J Bone Joint Surg Br. 1995;77(6):870-4.

[24]. Lieberman JR, Engstrom SM, Meneghini RM, SooHoo NF. Which factors influence the preservation of the osteonecrotic femoral head? Clin Orthop Relat Res. 2003;(417):162

[25]. Bhatia A, Pande S, Bansal M, Sharma S, Pradhan C. Avascular necrosis: from pathophysiology to treatment. J Orthop Traumatol. 2016;17(1):1-8.

[26]. Araujo R, Diniz JS, Lima JF, Dantas AT. Vascularized bone grafting for the treatment of osteonecrosis of the femoral head: A systematic review of the literature. Rev Bras Ortop. 2017;52(1):10-6.

[27]. Friedrichs J, Heller KD, Friederichs J, Freitag H, Vollert S, Meyer C, et al.Artificial intelligence in the diagnosis of avascular necrosis of the femoral head: the state of the

art. J Clin Orthop Trauma. 2020;11(Suppl 1):S63-S70.

[28]. Horner A, Yaffe MJ, Nauth A, O'Connor M. The role of imaging in the early diagnosis of avascular necrosis. Clin Orthop Relat Res. 2012;470(5):1295-302.

[29]. Kim YS, Lee JS, Yoon TR, Choi KS. The diagnostic accuracy of magnetic resonance imaging in femoral head osteonecrosis. Acta Radiol. 2007;48(5):520-5.

[30]. Zhao D, Deng ZH, Zhang JF, Wang CJ, Zhang W. Application of dual-energy CT in the evaluation of osteonecrosis of the femoral head. Osteoporos Int. 2015;26(1):139-45.

[31]. Kang HJ, Lee YK, Kim TK, Kim YS, Cho WJ, Kwon YJ. The predictive value of MRI findings for the hip joint collapse in patients with early-stage avascular necrosis. J Arthroplasty. 2011;26(8):1317-24.

[32]. Li Z, Wang D, Guo Y, Xie X, Shen Y, Li Y, et al. A systematic review and meta-analysis of early non-invasive diagnosis of avascular necrosis using functional imaging techniques. J Bone Joint Surg Am. 2016;98(11):911-9.

[33]. Tuncer S, Erdem Y, Karaoglu S, Yucel I. Accuracy of single-photon emission computed tomography in the diagnosis of avascular necrosis of the femoral head. Nucl Med Commun. 2010;31(7):574-9.

[34]. Schneider ME, Haller J, Horny R, Tiede S, Schmid B. Role of PET-CT in evaluating avascular necrosis. Eur J Nucl Med Mol Imaging. 2011;38(4):701-6.

[35]. Kriegmair M, Reiser M, Peters PE.New imaging techniques in the early diagnosis of osteonecrosis. Skeletal Radiol. 2003;32(3):143-7.

[36]. Tajima Y, Aizawa T, Saito S, Morita M, Hayashi K, Ishikawa T, et al. Early detection and treatment of avascular necrosis of the femoral head with a combination of core decompression and bone marrow-derived cell transplantation. J Bone Joint Surg Br. 2009;91(4):472-7.

[37]. Yin Z, Li J, Yuan Z, Wang X, Zhang J, Tang J, et al.The application of bone marrow-derived mesenchymal stem cells in avascular necrosis of the femoral head: A systematic review and meta-analysis. Stem Cell Res Ther. 2018;9(1):246.

[38]. Lee SY, Lee CH, Yoon YC, Son HM, Kwon KS, Ko YJ. The effectiveness of bisphosphonates in the treatment of femoral head osteonecrosis: A systematic review. Clin Rheumatol. 2011;30(7):927-33.

[39]. Chung M, Kuiper J, Lippiello L, Martin D, Hoag M. Core decompression versus total hip replacement for the management of femoral head necrosis: A meta-analysis. Orthopedics. 2014;37(12):870-9.

[40]. McLaughlin JR, Lee YK, Kline RM.Long-term outcomes of core decompression for avascular necrosis of the femoral head: A review of 238 cases. Bone Joint J. 2013;95(7):961-8.

[41]. Buechler U, Steiger C, Szabo R, Grossman T, McHenry B, Hochstrasser M. The role of AI in the future diagnosis of hip osteonecrosis: A survey of current applications. J Med Syst. 2021;45(7):54.

[42]. Narvaez JA, Pina LM, Lorrio AM, Marín FJ, González-Juanatey JR. Radiologic and MRI features in avascular necrosis of the femoral head: Diagnostic approach and new imaging biomarkers. Med Clin (Barc). 2020;154(6):233-7.

[43]. Oliva F, Latteri S, Amato M, Filardo G, Maffulli N. The role of biomarkers in the diagnosis of osteonecrosis of the femoral head. BMC Musculoskelet Disord. 2015;16:208.

[44]. Lezama A, Gutiérrez A, Peña A, Moreno G, Torres J. The future of molecular biomarkers in osteonecrosis. Int Orthop. 2018;42(5):1115-21.

[45]. Wang X, Li Y, Chen D, Zheng L, Yang Z. Non-surgical management of early-stage avascular necrosis of the femoral head. Clin Rheumatol. 2016;35(9):2351-9.

[46]. Patel RA, Hyer CF, Niazi F, Shields G. Advances in the management of avascular necrosis of the femoral head. J Am Acad Orthop Surg. 2013;21(5):283-90.

[47]. Zhang W, Wang Q, Wu S, Zhao D. The role of non-surgical treatments in the management of femoral head osteonecrosis. Clin Orthop Relat Res. 2014;472(6):1800-8.

[48]. Gomoll AH, McCauley JC, Pivovarov J, Williams RJ. Osteonecrosis of the femoral head: treatment options. J Am Acad Orthop Surg. 2016;24(7):e68-76.

[49]. Bannister GC. The diagnosis and management of avascular necrosis. Ann R Coll Surg Engl. 2013;95(7):443-8.